LOCALLY ADVANCED RECTAL CANCER (LARC)
Clinical trials for LOCALLY ADVANCED RECTAL CANCER (LARC) explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED RECTAL CANCER (LARC) trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED RECTAL CANCER (LARC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink rectal tumors before Surgery—Could spare some patients the knife
Disease control Not yet recruitingThis phase 2 trial tests a short course of radiation followed by a mix of chemotherapy, targeted therapy, and immunotherapy in 60 people with locally advanced rectal cancer. The goal is to see if this approach can make the tumor disappear completely before surgery, possibly allow…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy aims to spare organs in High-Risk rectal cancer
Disease control Not yet recruitingThis phase 3 trial tests whether short-course radiation followed by chemotherapy and an immunotherapy drug (serplulimab) works better than standard long-course chemoradiation for high-risk locally advanced rectal cancer. 612 patients will be randomly assigned to one of the two tr…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo may help avoid surgery in rectal cancer patients
Disease control Not yet recruitingThis study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (XELOX) after chemoradiation improves outcomes for people with locally advanced rectal cancer. About 270 participants will be randomly assigned to receive either the combination or chemoth…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could a diabetes drug boost rectal cancer treatment?
Disease control Not yet recruitingThis study tests whether adding a weight-loss medication (a GLP-1 drug) to standard chemo-radiation before surgery helps rectal cancer patients with a high BMI. About 42 participants will either get the drug plus standard treatment or standard treatment alone. Researchers will me…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: St. James's Hospital, Ireland • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Promising drug duo targets Hard-to-Treat HER2 cancers
Disease control Not yet recruitingThis study tests two drugs, zanidatamab and tislelizumab, combined with standard chemo or radiation for people with HER2-positive stomach or colorectal cancers. About 70 adults aged 18-75 will receive the treatment to see if it shrinks tumors and controls the disease. The goal is…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New triple therapy aims to shrink rectal tumors and avoid surgery
Disease control Not yet recruitingThis phase 2 trial tests a new approach for people with locally advanced rectal cancer that is not responding well to standard immunotherapy. Participants will receive short-course radiation, followed by an experimental drug (QL1706) that boosts the immune system, plus chemothera…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 26, 2026 18:06 UTC